The purpose of this study is to evaluate the safety, tolerability, and preliminary
efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants
with relapsed or refractory non-Hodgkin's lymphomas.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03930953.
Participants with relapsed or refractory non-Hodgkin's lymphomas (R/R NHL) who have
failed at least 2 lines of therapy (or have received at least one prior line of standard
therapy and are not eligible for any other therapy).
The dose escalation will evaluate the safety and tolerability of escalating doses of
CC-99282 in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and/or
relapsed or refractory follicular lymphoma (R/R FL) participants to determine the maximum
tolerated dose (MTD) of CC-99282 as monotherapy.
The dose expansion will further evaluate the safety and preliminary efficacy of single
agent CC-99282 or the safety and preliminary efficacy of CC-99282 in combination with
anti-lymphoma agents in participants with R/R DLBCL and NHL.
Part B Cohort B will further evaluate the potential effects of food on the PK and safety
of CC-99282.
Lead OrganizationCelgene Corporation
